{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T04:25:55Z","timestamp":1775535955034,"version":"3.50.1"},"reference-count":21,"publisher":"BMJ","issue":"12","funder":[{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"name":"KID-funding"},{"DOI":"10.13039\/501100007687","name":"Svenska L\u00e4kares\u00e4llskapet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007687","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Strategic Research Area"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Gut"],"accepted":{"date-parts":[[2018,1,14]]},"published-print":{"date-parts":[[2018,12]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      Gastric infection with\n                      <jats:italic>Helicobacter pylori<\/jats:italic>\n                      is a strong risk factor for non-cardia gastric adenocarcinoma. The aim of this study was to assess whether the risk of gastric adenocarcinoma and non-cardia gastric adenocarcinoma decreases after eradication treatment for\n                      <jats:italic>H. pylori<\/jats:italic>\n                      in a Western population.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>\n                      This was a nationwide, population-based cohort study in Sweden in 2005\u20132012. Data from the Swedish Prescribed Drug Registry provided information on\n                      <jats:italic>H. pylori<\/jats:italic>\n                      eradication treatment, whereas information concerning newly developed gastric adenocarcinoma was retrieved from the Swedish Cancer Registry. The risk of gastric adenocarcinoma and non-cardia gastric adenocarcinoma in individuals who had received\n                      <jats:italic>H. pylori<\/jats:italic>\n                      eradication treatment was compared with the background population of the corresponding age, sex and calendar year distribution, yielding standardised incidence ratios (SIRs) with 95% CIs.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>During the follow-up of 95\u2009176 individuals who had received eradication treatment (351\u2009018 person-years at risk), 75 (0.1%) developed gastric adenocarcinoma and 69 (0.1%) developed non-cardia gastric adenocarcinoma. The risk of gastric adenocarcinoma decreased over time after eradication treatment to levels below that of the corresponding background population. The SIRs were 8.65 (95% CI 6.37 to 11.46) for 1\u20133 years, 2.02 (95% CI 1.25 to 3.09) for 3\u20135 years and 0.31 (95% CI 0.11 to 0.67) for 5\u20137.5 years after eradication treatment. When restricted to non-cardia adenocarcinoma, the corresponding SIRs were 10.74 (95% CI 7.77 to 14.46), 2.67 (95% CI 1.63 to 4.13) and 0.43 (95% CI 0.16 to 0.93).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Eradication treatment for\n                      <jats:italic>H. pylori<\/jats:italic>\n                      seems to counteract the development of gastric adenocarcinoma and non-cardia gastric adenocarcinoma in this Western population.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/gutjnl-2017-315363","type":"journal-article","created":{"date-parts":[[2018,1,30]],"date-time":"2018-01-30T12:22:36Z","timestamp":1517314956000},"page":"2092-2096","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":106,"title":["<i>Helicobacter pylori<\/i>\n                    eradication treatment and the risk of gastric adenocarcinoma in a Western population"],"prefix":"10.1136","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1299-2441","authenticated-orcid":false,"given":"Eva","family":"Doorakkers","sequence":"first","affiliation":[{"name":"Upper Gastrointestinal Surgery, Department of Molecular Medicine and Surgery, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5143-5448","authenticated-orcid":false,"given":"Jesper","family":"Lagergren","sequence":"additional","affiliation":[{"name":"Upper Gastrointestinal Surgery, Department of Molecular Medicine and Surgery, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden"},{"name":"School of Cancer Sciences, King\u2019s College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars","family":"Engstrand","sequence":"additional","affiliation":[{"name":"Centre for Translational Microbiome Research, Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden"},{"name":"Science for Life Laboratory, Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0137-447X","authenticated-orcid":false,"given":"Nele","family":"Brusselaers","sequence":"additional","affiliation":[{"name":"Centre for Translational Microbiome Research, Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden"},{"name":"Science for Life Laboratory, Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2018,1,30]]},"reference":[{"key":"2025121306233068000_67.12.2092.1","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1001\/jamaoncol.2015.0735","article-title":"The global burden of cancer 2013","volume":"1","author":"Fitzmaurice","year":"2015","journal-title":"JAMA Oncol"},{"key":"2025121306233068000_67.12.2092.2","unstructured":"The National Board of Health and Welfare. Cancer incidence in Sweden 2014. Sweden: The National Board of Health and Welfare, 2015."},{"key":"2025121306233068000_67.12.2092.3","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2796.2003.01119.x"},{"key":"2025121306233068000_67.12.2092.4","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-014-3063-0"},{"key":"2025121306233068000_67.12.2092.5","doi-asserted-by":"publisher","DOI":"10.1177\/2050640615623369"},{"key":"2025121306233068000_67.12.2092.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1001110"},{"key":"2025121306233068000_67.12.2092.7","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g3174"},{"key":"2025121306233068000_67.12.2092.8","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1093\/jnci\/djw132","article-title":"Eradication of Helicobacter pylori and gastric cancer: a systematic review and meta-analysis of cohort studies","volume":"108","author":"Doorakkers","year":"2016","journal-title":"J Natl Cancer Inst"},{"key":"2025121306233068000_67.12.2092.9","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1080\/00365521.2017.1303844","article-title":"Helicobacter pylori eradication in the Swedish population","volume":"52","author":"Doorakkers","year":"2017","journal-title":"Scand J Gastroenterol"},{"key":"2025121306233068000_67.12.2092.10","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2016-312288"},{"key":"2025121306233068000_67.12.2092.11","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2013.411"},{"key":"2025121306233068000_67.12.2092.12","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1294"},{"key":"2025121306233068000_67.12.2092.13","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/91.9.786"},{"key":"2025121306233068000_67.12.2092.14","unstructured":"The National Board of Health and Welfare. Causes of death 2014. Sweden: The National Board of Health and Welfare, 2015."},{"key":"2025121306233068000_67.12.2092.15","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-11-450"},{"key":"2025121306233068000_67.12.2092.16","unstructured":"Breslow NE , Day NE . Statistical methods in cancer research. Volume II:\u00a0the design and analysis of cohort studies. IARC Sci Publ 1987:1\u2013406."},{"key":"2025121306233068000_67.12.2092.17","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwv254"},{"key":"2025121306233068000_67.12.2092.18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-5378.2006.00414.x"},{"key":"2025121306233068000_67.12.2092.19","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.15.4290"},{"key":"2025121306233068000_67.12.2092.20","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djs003"},{"key":"2025121306233068000_67.12.2092.21","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.25337"}],"container-title":["Gut"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/gutjnl-2017-315363","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T14:23:39Z","timestamp":1765635819000},"score":1,"resource":{"primary":{"URL":"https:\/\/gut.bmj.com\/lookup\/doi\/10.1136\/gutjnl-2017-315363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,30]]},"references-count":21,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2018,11,9]]},"published-print":{"date-parts":[[2018,12]]}},"alternative-id":["10.1136\/gutjnl-2017-315363"],"URL":"https:\/\/doi.org\/10.1136\/gutjnl-2017-315363","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.732587214.793553502","asserted-by":"object"}]},"ISSN":["0017-5749","1468-3288"],"issn-type":[{"value":"0017-5749","type":"print"},{"value":"1468-3288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,30]]}}}